Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

1.

Lymphoproliferative disorders in patients undergoing living-related liver transplantation.

Egawa H, Inomata Y, Uemoto S, Asonuma K, Kiuchi T, Oh-ishi T, Matsui A, Tanaka K.

Transplant Proc. 1998 Feb;30(1):136-7. No abstract available.

PMID:
9474982
[PubMed - indexed for MEDLINE]
2.

Posttransplantation lymphoproliferative disorders in pediatric patients undergoing liver transplantation.

Koh BY, Rosenthal P, Medeiros LJ, Osorio RW, Roberts JP, Ascher NL, Gelb AB.

Arch Pathol Lab Med. 2001 Mar;125(3):337-43.

PMID:
11231479
[PubMed - indexed for MEDLINE]
3.

Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.

Guthery SL, Heubi JE, Bucuvalas JC, Gross TG, Ryckman FC, Alonso MH, Balistreri WF, Hornung RW.

Transplantation. 2003 Apr 15;75(7):987-93.

PMID:
12698085
[PubMed - indexed for MEDLINE]
4.

Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.

Ellis D, Jaffe R, Green M, Janosky JJ, Lombardozzi-Lane S, Shapiro R, Scantlebury V, Vivas C, Jordan ML.

Transplantation. 1999 Oct 15;68(7):997-1003.

PMID:
10532541
[PubMed - indexed for MEDLINE]
5.

Sirolimus in pediatric liver transplantation: a single-center experience.

Gibelli NE, Tannuri U, Pinho-Apezzato ML, Tannuri AC, Maksoud-Filho JG, Andrade WC, Velhote MC, Santos MM, Ayoub AA, Marques da Silva M.

Transplant Proc. 2009 Apr;41(3):901-3. doi: 10.1016/j.transproceed.2009.01.054.

PMID:
19376384
[PubMed - indexed for MEDLINE]
6.

Significance of serial real-time PCR monitoring of EBV genome load in living donor liver transplantation.

Matsukura T, Yokoi A, Egawa H, Kudo T, Kawashima M, Hirata Y, Tanaka H, Kagajo K, Wada H, Tanaka K.

Clin Transplant. 2002 Apr;16(2):107-12.

PMID:
11966780
[PubMed - indexed for MEDLINE]
7.

Paediatric liver transplantation: indications, timing and medical complications.

Cox KL, Berquist WE, Castillo RO.

J Gastroenterol Hepatol. 1999 May;14 Suppl:S61-6.

PMID:
10382641
[PubMed - indexed for MEDLINE]
8.

Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects.

Kiuchi T, Tanaka K, Inomata Y, Uemoto S, Satomura K, Egawa H, Uyama S, Sano K, Okajima H, Yamaoka Y.

Transplant Proc. 1996 Dec;28(6):3171-2. No abstract available.

PMID:
8962229
[PubMed - indexed for MEDLINE]
9.

Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease.

Smets F, Latinne D, Bazin H, Reding R, Otte JB, Buts JP, Sokal EM.

Transplantation. 2002 May 27;73(10):1603-10.

PMID:
12042647
[PubMed - indexed for MEDLINE]
10.

Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients.

Cacciarelli TV, Reyes J, Jaffe R, Mazariegos GV, Jain A, Fung JJ, Green M.

Pediatr Transplant. 2001 Oct;5(5):359-64.

PMID:
11560756
[PubMed - indexed for MEDLINE]
11.

The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.

Younes BS, McDiarmid SV, Martin MG, Vargas JH, Goss JA, Busuttil RW, Ament ME.

Transplantation. 2000 Jul 15;70(1):94-9.

PMID:
10919581
[PubMed - indexed for MEDLINE]
12.

Tacrolimus in pediatric liver transplantation.

Reding R.

Pediatr Transplant. 2002 Dec;6(6):447-51. Review. No abstract available.

PMID:
12453195
[PubMed - indexed for MEDLINE]
13.

Neoral is superior to FK 506 in liver transplantation.

Levy GA.

Transplant Proc. 1998 Aug;30(5):1812-5. Review. No abstract available.

PMID:
9723293
[PubMed - indexed for MEDLINE]
14.

Thirteen years' experience in pediatric liver transplantation: differences between tacrolimus and cyclosporine.

Zajicek A, Esquivel C, Millan M, Cox K, Berquist R, Berquist W.

Transplant Proc. 2002 Aug;34(5):1976-8. No abstract available.

PMID:
12176653
[PubMed - indexed for MEDLINE]
15.

The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.

Kogan-Liberman D, Burroughs M, Emre S, Moscona A, Shneider BL.

J Pediatr Gastroenterol Nutr. 2001 Oct;33(4):445-9.

PMID:
11698761
[PubMed - indexed for MEDLINE]
16.

Cumulative experience with pediatric living related liver transplantation.

Colombani PM, Lau H, Prabhakaran K, Maley W, Wise B, Schwarz K, Klein A.

J Pediatr Surg. 2000 Jan;35(1):9-12.

PMID:
10646765
[PubMed - indexed for MEDLINE]
17.

Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.

Cacciarelli TV, Green M, Jaffe R, Mazariegos GV, Jain A, Fung JJ, Reyes J.

Transplantation. 1998 Oct 27;66(8):1047-52.

PMID:
9808490
[PubMed - indexed for MEDLINE]
18.

Decreasing the Epstein-Barr virus load by adjusting the FK506 blood level.

Orii T, Ohkohchi N, Satomi S, Hoshino Y, Kimura H.

Transpl Int. 2002 Nov;15(11):529-34. Epub 2002 Oct 3.

PMID:
12461655
[PubMed - indexed for MEDLINE]
19.

Monitoring of Epstein-Barr virus serology in children after liver transplant: lack of clinical correlation.

Granot E, Doron D, Morag R.

Transplant Proc. 2000 Jun;32(4):706-7. No abstract available.

PMID:
10856551
[PubMed - indexed for MEDLINE]
20.

Long-term use of FK 506 in living related liver transplantation.

Uemoto S, Tanaka K, Tokunaga Y, Nishizawa T, Sawada H, Katoh H, Yamamoto E, Yamaoka Y, Ozawa K.

Transpl Int. 1994;7 Suppl 1:S81-4.

PMID:
11271341
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk